[ad_1]
Photo by Paul Ellis (AFP / Scanpix)
British pharmaceutical company AstraZeneca reports that its potential COVID-19 vaccine has elicited a similar immune response in both young and older adults.
AstraZeneca, which is developing the vaccine in collaboration with researchers at the University of Oxford, says that the initial effect of the vaccine in older people has been less.
According to the World Health Organization, COVID-19 is more severe in older people (as well as people with comorbid illnesses) than in others.
The results further improve the safety and overall immunogenicity of AZD1222, says the AstraZeneca spokesperson, given the name of the technical vaccine being developed.
The AstraZeneca report is likely to raise hopes that the COVID-19 vaccine will be developed by the end of the year, according to CNBC.
Many drug manufacturers and scientists are working to develop a safe and effective vaccine to stop coronavirus infections, which have cost more than 1.15 million people. life around the world, spread.
The potential of the vaccines is currently in the clinical trial phase, with some of the final stages of the trial seeking formal approval. The AstraZeneca vaccine is considered to be one of the fastest to gain regulatory approval.
Rayti komentar
[ad_2]
